Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High vs Low LMWH Dosages in Severe COVID-19
NCT04408235Phase 3
Key facts
- Status
- Unknown
- Start
- Jun 2020
- Primary completion
- Jun 2021
- Countries
- 1
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
- Modality
- Recombinant Proteins and Enzymes
- Drugs
- enoxaparin
- Conditions
- coronavirus disease 2019 (COVID-19)pneumoniacoagulopathy
01
Overview
Phase 3, randomised, open-label trial of enoxaparin in coronavirus disease 2019 (COVID-19), pneumonia and coagulopathy, sponsored by Azienda Ospedaliera Universitaria Policlinico. Primary endpoint: Clinical worsening at 30 days. Status: unknown.
02
Design
- Study design
- RandomizedOpen-label
03
Who it enrols
Hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation.
04
Endpoints
Primary
Clinical worsening
Secondary
Mortality at 30 days
Major bleeding risk
Acute Myocardial Infarction
Arterial or venous thromboembolism
Need for mechanical ventilation
Beyond the preview
Go deeper on NCT04408235.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04408235.